No Data
No Data
Needham Maintains Artiva Biotherapeutics(ARTV.US) With Buy Rating, Maintains Target Price $23
Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics Price Target Maintained With a $23.00/Share by Needham
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support
12 Health Care Stocks Moving In Monday's Intraday Session
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference